The significant outperformance of Boston Scientific over the past decade, as highlighted by its 17.13% annualized return, suggests a strong and consistent growth trajectory. This historical performance, coupled with a substantial market capitalization of $95.60 billion, indicates a positive outlook for the company's stock. Investors may view this track record as a sign of the company's resilience and potential for continued growth, likely contributing to a positive short-term impact on the stock price.